How a single-chain glycoprotein became the performance community’s most promising—and most misunderstood—myostatin inhibitor. Clinical gene therapy data vs. underground peptide injection. What works. What doesn’t. What we don’t know.
Follistatin is the most validated myostatin inhibitor in preclinical biology. The science backing myostatin suppression as a lever for muscle hypertrophy is bulletproof: knock out the myostatin gene, and muscle mass skyrockets. That happens in cattle (Belgian Blue), in dogs (whippet “bully” phenotype), in mice, in humans with myostatin mutations (rare, but documented). The mechanism works.
But there is a chasm between the mechanism and the application. The clinical evidence validating follistatin comes from AAV1-follistatin gene therapy trials in Becker muscular dystrophy and sporadic inclusion body myositis—trials that show improved muscle function and walking distance in real humans. That gene therapy delivers sustained, intramuscular follistatin expression over months. By contrast, the peptide form—follistatin 344, injected subcutaneously by athletes and self-experimenters—has no published human safety or efficacy data. Zero. The peptide is rapidly cleared, protease-sensitive, and has a pharmacokinetic profile fundamentally different from gene therapy. The performance community has extrapolated from mechanism and animal models, not human evidence.
This article dissects both. We examine what follistatin is, how it works, what the gene therapy trials show, what community use looks like, and—crucially—the gaps in our knowledge. We do not assume benefit. We follow the evidence.
Contents
- Quick Facts
- What Is Follistatin?
- Origins and Discovery
- Mechanism of Action
- Key Research Areas
- Claims vs. Evidence
- Human Evidence Landscape
- Safety, Risks, and Limitations
- Legal and Regulatory Status
- Research Protocols
- Dosing in Published Research
- Dosing in Self-Experimentation
- Frequently Asked Questions
- Related Peptides and Comparisons
- Summary
- References
- Further Reading
- Disclaimer
Quick Facts
The research moves fast. We read all of it so you don’t have to.
New compound reviews, evidence updates, and protocol analysis — sourced, cited, and written for people who actually read the studies.
What Is Follistatin?
Follistatin is a single-chain glycoprotein—a protein with sugar chains attached—synthesized primarily in the follicles of the ovary, and also expressed in bone, muscle, and other tissues. It was first isolated and characterized in the 1980s as a hormone that suppresses follicle-stimulating hormone (FSH) secretion from the anterior pituitary gland. Its name reflects that original discovery: “follicle statin” — a statin (suppressant) of follicle function.
But the protein has a much broader role. Follistatin is a ligand-binding protein—a molecular sponge—that binds members of the transforming growth factor-beta (TGF-β) superfamily. At high affinity, follistatin binds myostatin (growth and differentiation factor 8, GDF8), the primary negative regulator of skeletal muscle mass. It also binds activins A and B, which regulate FSH secretion and have roles in bone and immune function. And it binds other TGF-β ligands at lower affinity.
There are three main isoforms of human follistatin, generated by alternative splicing:
- FS288: 288 amino acids; found in some tissues, less common.
- FS315 (sometimes called FS344 in literature, but technically FS315 is membrane-bound): 315 amino acids after removal of the signal peptide; this is the circulating form and the isoform typically discussed in the performance community as “FS344” or “FS315.”
- FS344: 344 amino acids before signal peptide cleavage; thus FS344 refers to the pre-processed form, and after cleavage becomes FS315. The terminology is inconsistent in the literature, but the key point: the circulating, soluble form is ~315 amino acids and ~35 kDa in molecular weight.
For the purposes of this article, we refer to the performance-relevant isoform as follistatin 344/315—the circulating form used in peptide preparations. The distinction matters for pharmacokinetics and mechanism, but what matters most to muscle is the binding and inactivation of myostatin.
Origins and Discovery
Follistatin was first described in 1985 when Ying and colleagues isolated a peptide from porcine follicular fluid that inhibited FSH secretion in pituitary cultures. The name and concept emerged from that work. By the early 1990s, the protein was cloned in humans, and its role in bone, muscle, and endocrine regulation became apparent.
The myostatin connection came later. Myostatin itself was identified in 1997 by Se-Jin Lee’s group at Johns Hopkins University. They found that myostatin-null mice were dramatically more muscular than wild-type controls—and crucially, heterozygous mice (one mutant allele) also showed elevated muscle mass. This established myostatin as a genuine brake on muscle growth and a legitimate therapeutic target for muscle-wasting diseases.
By the early 2000s, researchers realized that follistatin, already known to exist in muscle, was also a myostatin-binding protein. The next logical step: use follistatin as a myostatin inhibitor. This led to a cascade of preclinical studies in mice, dogs, and non-human primates, all showing that increased follistatin expression (via adeno-associated virus, AAV, or transgenic overexpression) resulted in significant muscle hypertrophy and improved muscle function in models of muscular dystrophy.
The first human application came decades later: in the 2010s, researchers at Nationwide Children’s Hospital, led by Jerry Mendell, began a Phase I/II trial of AAV1-follistatin gene therapy in patients with Becker muscular dystrophy and sporadic inclusion body myositis. This is, to date, the only human data on follistatin’s efficacy and safety in augmenting muscle.
In parallel, the underground performance-enhancement community began experimenting with recombinant follistatin peptides in the 2010s. The peptide form was never pursued clinically for muscle disease (because the gene therapy platform is more elegant and effective), but it became popular in bodybuilding and strength sports. The community did not wait for clinical validation.
Mechanism of Action
Myostatin Inhibition
Myostatin is a secreted protein produced primarily by skeletal muscle cells. It is cleaved into an active ligand and a pro-domain; the active dimer then binds to activin receptor type IIB (ActR2B) on muscle cell membranes. This triggers a phosphorylation cascade (via SMAD2/3 signaling) that ultimately suppresses mTOR activity and reduces protein synthesis while increasing protein degradation. The net effect: muscle breakdown, smaller fibers, reduced mass.
Follistatin is a high-affinity binder of myostatin. When follistatin is present in the extracellular space, it preferentially sequesters myostatin ligand before the ligand can bind ActR2B. This prevents the myostatin signaling cascade from initiating. Muscle cells are then free to build protein at their baseline rate, enhanced by training and amino acids. The result: myostatin-suppressed muscle grows larger and stronger, all else equal.
The biology is rock-solid. Myostatin-null animals (Belgian Blue cattle, whippet “bully” dogs, and intentional knockouts in mice and other species) exhibit dramatic, coordinated muscle hypertrophy across all skeletal muscles. Heterozygous animals show intermediate gains. There is no ambiguity: myostatin is a genuine brake on muscle mass.
Activin Binding and Off-Target Effects
Follistatin does not only bind myostatin. It also binds activin A and activin B at high affinity. Activins are TGF-β superfamily members involved in multiple physiological processes, including regulation of FSH and LH secretion from the pituitary, immune function, and bone remodeling.
When follistatin binds and inactivates activins, it can suppress FSH levels. This is actually how follistatin was first discovered and named—its primary physiological role is likely as a negative regulator of FSH. In women, low FSH can suppress ovulation and menstrual cycles. In men, FSH supports spermatogenesis; suppression can reduce sperm count and fertility. This off-target effect is particularly relevant to the peptide form, where we have no human data on whether chronic activin suppression causes reversible or irreversible reproductive harm.
Follistatin also binds other TGF-β ligands (GDF11, BMP7, and others) at lower affinity. The full range of its biological effects when injected systemically is not well-characterized in humans.
Key Research Areas
AAV1-Follistatin Gene Therapy in Muscular Dystrophy
The most rigorous human data comes from the Phase I/II trial of AAV1-follistatin in Becker muscular dystrophy and inclusion body myositis (IBM), led by Jerry Mendell at Nationwide Children’s Hospital and published and presented between 2018 and 2023. This trial involved direct intramuscular injection of AAV1 carrying the follistatin gene into specific muscles (e.g., tibialis anterior, quadriceps). The virus integrates into muscle cell nuclei, and cells begin expressing endogenous follistatin mRNA and protein continuously.
Results in Becker MD patients showed improvements in muscle strength, walking distance, and muscle imaging (MRI/ultrasound) compared to baseline. In IBM patients, the therapy slowed functional decline and showed measurable increases in treated muscle volume. No serious adverse events attributed to follistatin were reported; some patients had mild, transient immune responses (likely to the AAV capsid, not follistatin itself).
Critically, this therapy achieves sustained, intramuscular follistatin expression over months to years. A single injection provides continuous production of follistatin by the transduced muscle cells. This is fundamentally different from bolus peptide injection, where a dose of recombinant follistatin is injected subcutaneously, enters the bloodstream, circulates for hours, and is then cleared or degraded.
Preclinical Models: Transgenic and Viral Overexpression
Decades of preclinical work have shown that muscle-specific overexpression of follistatin (via transgenic or viral vectors) results in:
- Significant increases in muscle mass (20–50% hypertrophy in some models).
- Improved muscle function (strength, endurance, resistance to fatigue).
- Protection against muscle wasting in models of cancer cachexia, aging, and dystrophy.
- No evidence of adverse cardiac effects in these models, though chronic myostatin suppression can lead to mild cardiac hypertrophy (of unclear clinical significance).
These studies are typically short-term (weeks to months) and involve muscle-specific expression. They validate the mechanism but do not directly translate to systemic peptide injection in humans.
Myostatin Inhibitors Beyond Follistatin
Other compounds targeting myostatin are in development: monoclonal antibodies (e.g., domagrozumab, MYO-029), ActR2B ligand traps (e.g., ACE-031, bimagrumab), and engineered proteins (e.g., GDF8 prodomain variants). Some have advanced to Phase II and Phase III trials in Duchenne MD and other wasting diseases. None have been approved by the FDA for routine use, though some show promise. The existence of competing approaches underscores both the therapeutic potential of myostatin inhibition and the difficulty of translating it into safe, effective drugs.
Claims vs. Evidence Table
| Claim | Evidence Tier | Status |
|---|---|---|
| Myostatin inhibition increases muscle mass in animals. | Preclinical (In Vivo) | Validated. Decades of studies in mice, dogs, cattle, primates. Myostatin-null animals are massively hypertrophied. |
| AAV1-follistatin gene therapy improves muscle function in Becker MD and IBM. | Clinical Trials (Phase I/II) | Validated. Mendell et al., intramuscular injection, sustained expression, improved walking distance and strength. Limited sample sizes; longer-term data pending. |
| Follistatin peptide injection increases muscle mass in humans. | No Human Data | Unvalidated. Zero published clinical trials. Community reports anecdotal muscle gains; no controlled evidence. Pharmacokinetics and bioavailability unknown. |
| Follistatin peptide is safe for long-term use. | No Human Data | Unknown. No human safety studies. Gene therapy data shows short-term safety but does not address systemic peptide effects. |
| Follistatin does not suppress reproductive hormones at therapeutic doses. | No Human Data | Unvalidated. Activin suppression is likely to lower FSH; reproductive effects unknown in humans with peptide injection. |
| Myostatin suppression is fully reversible upon cessation. | Theoretical | Likely but unproven. Myostatin protein is short-lived; stopping follistatin allows myostatin to accumulate again. Reversibility of any hormone suppression unknown. |
The research moves fast. We read all of it so you don’t have to.
New compound reviews, evidence updates, and protocol analysis — sourced, cited, and written for people who actually read the studies.
Human Evidence Landscape
Clinical Trials
As of early 2026, there is exactly one completed-or-ongoing human trial of follistatin: the AAV1-follistatin gene therapy study at Nationwide Children’s Hospital (NIH trial NCT02064569 and related trials). This trial enrolled patients with Becker MD and inclusion body myositis; the primary endpoint was safety and feasibility, with secondary endpoints on muscle strength and function. Results have been reported in multiple presentations and a published study in Molecular Therapy.
Key findings: Intramuscular injection of AAV1-follistatin was well-tolerated. Treated muscles showed increased size on imaging (MRI, ultrasound) and improved strength in some patients. Walking distance improved in some Becker MD patients. No serious adverse events were directly attributed to follistatin; some patients had mild immune responses (anti-AAV antibodies), which is common with viral vector therapies and does not necessarily reflect follistatin toxicity.
Limitations: Small sample size (fewer than 20 patients per arm). Short follow-up (12–24 months at time of publication). Intramuscular, not systemic, delivery. Measures were often qualitative or anecdotal. No reproductive hormone monitoring.
What this tells us about peptide injection: The sustained expression model (gene therapy) validates myostatin inhibition as a mechanism. It does NOT tell us whether bolus peptide injection is safe, effective, or free of long-term reproductive consequences. Different pharmacokinetics, different target tissue exposure, different duration of action.
Observational and Anecdotal Data
In performance and strength sports communities, follistatin peptide has been used off-label since roughly 2010–2012. Numerous athletes and self-experimenters have documented their experiences on forums, social media, and underground training logs. Reported outcomes typically include:
- Muscle gains within 2–6 weeks of starting; magnitude often described as 5–10 lbs of lean mass per cycle (10–30 days).
- Improved strength and training capacity.
- Reduced soreness and faster recovery.
- In some cases, sexual dysfunction or testicular atrophy (anecdotal, not confirmed in any formal study).
- Variable results; some report dramatic gains, others minimal.
Evidence tier: These are anecdotal reports, not controlled trials. No placebo control, no double-blinding, confounded by concurrent AAS use, training variation, diet, and expectancy bias. The variability in reported effects is consistent with placebo, dose uncertainty, or variable product quality (purity of peptides sourced from unregulated suppliers is not verified).
Internet and “Underground” Chemistry”
Follistatin peptide is not available by prescription. It is manufactured by legitimate research peptide suppliers (often offshore, in China, India, or Eastern Europe) and sold as “research chemical—not for human consumption.” The purity, sterility, and identity of these products are not regulated by the FDA and are not independently verified. Contamination, mis-labeling, and variable potency are common problems with unregulated peptide suppliers.
The literature of underground use (forums such as Reddit’s r/steroids, various Facebook groups, and private Discord servers) provides qualitative information but is not suitable for evidence-based claims about safety or efficacy. Users often lack baseline measurements, blinding, and controlled conditions. Reporting bias is extreme: users who achieve gains post about them; users who experience harms may not disclose them publicly.
Safety, Risks, and Limitations
Reproductive and Endocrine Effects
The most plausible and concerning risk from follistatin peptide is suppression of FSH via activin inhibition. In humans, FSH is essential for spermatogenesis in men and ovulation in women. Activin A and B are involved in pituitary regulation of FSH; blocking activins can suppress FSH levels significantly.
To what degree and over what timeframe does follistatin peptide suppress FSH in humans? Unknown. No one has measured it. The AAV gene therapy trial did not report reproductive hormone panels. Underground users report anecdotal cases of sexual dysfunction and testicular atrophy, but without hormone data, causation cannot be established.
Risk assessment: Systemic follistatin peptide has a plausible mechanism to suppress FSH. Chronic FSH suppression is likely to reduce fertility and sexual function. Reversibility upon cessation is unknown. For men, this could mean temporary or permanent reduction in sperm count; for women, suppressed ovulation and menstrual dysfunction.
Cardiac and Systemic Effects
Myostatin is not unique to skeletal muscle; it is expressed in cardiac muscle as well. Some preclinical data suggest that myostatin suppression can lead to cardiac hypertrophy (enlargement). Whether this is compensatory (benign) or pathological (risk of arrhythmia or heart failure) is unclear. The AAV gene therapy trial reported no obvious cardiac complications, but imaging was not a primary focus.
Chronic systemic elevation of follistatin could also affect bone, immune function, and other tissues expressing activin receptors. Again, no human data.
Protease Sensitivity and Bioavailability
Follistatin is a glycoprotein, ~35 kDa in size. It is susceptible to proteolytic degradation and is unlikely to be orally bioavailable (though no one has formally tested this). When injected subcutaneously, it will be absorbed into the bloodstream over minutes to hours, circulate, and be cleared by the kidneys and/or proteolytic breakdown. Half-life estimates in rodent models suggest 10–30 minutes; human data are unavailable.
This means that peptide injection achieves transient, bolus-style elevation of serum follistatin—very different from the sustained intramuscular expression achieved by gene therapy. The practical implication: if you want myostatin suppression, you need to inject frequently (daily or every other day), or use a long-acting depot formulation (which does not exist clinically).
Injection Site Reactions
Subcutaneous injection of recombinant peptides can provoke local inflammation, swelling, bruising, or infection if sterile technique is not maintained. No formal incidence data exist for follistatin. Underground reports mention occasional injection site lipohypertrophy (fat deposits at injection sites) with chronic peptide injection, a common finding with repeated SC insulin or GLP-1 use.
Quality and Identity Concerns
Follistatin peptides sold online are manufactured in unregulated settings. Testing for identity, purity, sterility, and potency is not required. Users are vulnerable to:
- Mis-labeled products (peptide labeled as follistatin but containing something else or nothing at all).
- Contamination with bacterial endotoxins or other pyrogens, leading to fevers and systemic reactions.
- Oxidized or denatured peptide with reduced biological activity.
- Misdosing due to unclear concentration or volume.
Legal and Regulatory Status
WADA Prohibition
Follistatin and other myostatin inhibitors are explicitly prohibited by the World Anti-Doping Agency (WADA) under the 2025 Prohibited List, Section S4.4 (Myostatin Inhibitors). The prohibition applies to all forms: peptides, monoclonal antibodies, and small-molecule inhibitors. Both in-competition and out-of-competition use are banned.
Testing: WADA and national anti-doping organizations are developing and refining assays for myostatin inhibitor detection. Direct detection of follistatin peptide in serum is feasible via mass spectrometry (tandem MS/MS). Indirect markers (e.g., myostatin:follistatin ratio in serum) may also be used.
Consequences: For sanctioned athletes in tested sports, using follistatin carries the risk of a positive test, disqualification, loss of medals or records, and a ban from competition.
FDA Regulatory Status
Follistatin peptide is not an FDA-approved drug. It is not legal to manufacture, distribute, or sell follistatin for human use in the United States. However, it is available from research peptide suppliers marketed as “not for human consumption” and sold for “research purposes only.” This is a common regulatory loophole: the suppliers claim they are not marketing for human use, but the end-user intent is evident.
The AAV1-follistatin gene therapy (designated a gene therapy product, not a traditional drug) is in clinical trials and may eventually receive FDA approval for specific muscle-wasting diseases (Becker MD, IBM, others). As of 2026, it is not approved.
International Regulations
Follistatin is similarly unregulated in most countries. It is not approved in the EU, Canada, Australia, or other major markets. Use is technically illegal for human consumption in most jurisdictions, though enforcement against individual self-experimenters is rare. Manufacturing, distribution, and marketing of follistatin peptides for human use is illegal in most countries.
Research Protocols
Published research on follistatin in animals typically employs one of three approaches:
Transgenic Muscle-Specific Overexpression
Follistatin cDNA is inserted into the mouse or rat genome under the control of a muscle-specific promoter (e.g., MCK, myogenin, or human skeletal actin promoter). Transgenic animals produce follistatin constitutively in all skeletal muscles. Results: muscle mass increases 20–50% above wild-type by 8–12 weeks of age; strength increases proportionally.
Viral Vector Delivery (AAV or Adenovirus)
Follistatin cDNA is packaged into an adeno-associated virus (AAV) or adenoviral vector, often with intramuscular injection into a target muscle (e.g., tibialis anterior, quadriceps). The virus transfects muscle cells, and those cells express follistatin from the viral genome. In rodent studies, this approach results in localized muscle hypertrophy (30–50% increase) and can protect against wasting in models of muscular dystrophy or cancer cachexia.
Recombinant Follistatin Peptide Injection
Purified recombinant follistatin is injected intravenously, intraperitoneally, or subcutaneously in rodents. Early studies (1990s–2000s) found that systemic follistatin injection could modestly increase muscle mass in normal mice and more substantially protect muscle in disease models. However, the transient nature of bolus injection (quick clearance) limits effect size compared to sustained expression via transgenes or AAV.
Human Gene Therapy Protocol (Mendell et al.)
AAV1 carrying follistatin cDNA is injected directly into specific muscles under ultrasound or electrophysiological guidance. Single dose to one or a few muscles per patient. Follow-up: imaging (MRI, ultrasound), strength testing, walking distance, muscle biopsy in some cases. Immune monitoring: anti-AAV antibodies, systemic inflammatory markers.
Dosing in Published Research
| Study Type | Species/Model | Dose and Route | Duration | Outcome |
|---|---|---|---|---|
| Transgenic Overexpression | Mouse (MCK-FS transgenic) | Constitutive muscle-specific expression; endogenous follistatin levels ~2–5× normal | Lifelong | 20–50% muscle hypertrophy; normal lifespan; no obvious pathology |
| AAV1-Follistatin (Preclinical) | Mdx mouse (Duchenne MD model) | 5–10 × 10^11 viral genomes (vg) per muscle, IM injection | 12 weeks | 30–40% increase in injected muscle; reduced pathology on histology |
| Recombinant FS Peptide IV | Mouse (normal) | 0.5–2 mg/kg, intravenous bolus | Single dose or repeated daily for 2–4 weeks | Modest muscle growth (5–15%); transient due to rapid clearance |
| AAV1-FS Gene Therapy (Phase I/II, Human) | Becker MD, IBM patients | 1.3 × 10^12 vg per muscle, direct intramuscular injection to 1–2 muscles | Single injection; followed up to 24 months | Improved muscle strength, walking distance; increased muscle volume on MRI/ultrasound; well-tolerated |
Dosing in Self-Experimentation
| Protocol | Dose (mcg) | Route | Frequency | Cycle Length | Reported Rationale | Reported Outcomes (Anecdotal) |
|---|---|---|---|---|---|---|
| Low-Dose Cycle | 50–100 mcg | Subcutaneous | Daily | 10–14 days | Minimize side effects | Modest gains (2–5 lbs); minimal hormonal disruption reported |
| Standard Cycle | 100–200 mcg | Subcutaneous | Daily | 15–30 days | “Sweet spot” between efficacy and side effects | Reported gains 5–15 lbs; some sexual dysfunction reported |
| High-Dose Cycle | 200–400 mcg | Subcutaneous | Daily or BID (twice daily) | 20–30 days | Maximize muscle gains | Reported gains 10–20+ lbs; higher rate of adverse reports (sexual dysfunction, gynecomastia from hormonal shifts) |
| Stacked with AAS | 100–150 mcg | Subcutaneous | Daily | Concurrent with AAS cycle (8–16 weeks) | Synergistic muscle growth via complementary mechanisms (follistatin = myostatin inhibition; AAS = anabolic) | Users report additive or synergistic gains; hormonal disruption likely higher |
Note: No published human trials inform these doses. Community dosing is derived from: (1) rough extrapolation from animal studies, (2) trial-and-error reports on forums, and (3) economic factors (price per peptide vial). No optimal dose has been established in humans. Individual variation in response is likely high due to differences in body composition, muscle mass, genetics, concurrent training, and nutrition.
Frequently Asked Questions
No clinical evidence compares them head-to-head. Anabolic steroids (testosterone, nandrolone, etc.) promote muscle protein synthesis via androgen receptors and have decades of use data, albeit with known side effects (cardiac, hepatic, reproductive). Follistatin works via myostatin inhibition and has essentially zero human efficacy data for peptide injection—only gene therapy data, which shows muscle benefit in disease but is not a direct comparison. In preclinical models, myostatin inhibitors and androgens activate different signaling pathways and may have additive effects. Underground anecdotes suggest some users achieve greater gains by stacking follistatin with AAS, but this is not controlled evidence. For someone willing to use anabolic steroids, adding follistatin is speculative.
No. Follistatin is a ~35 kDa protein and will be digested by stomach and intestinal proteases. Oral bioavailability is essentially zero (never formally tested, but the logic is sound). All published research uses injection (subcutaneous, intramuscular, intravenous, or viral vector-mediated expression). Oral peptide products marketed as “follistatin” are scams or misrepresented compounds.
Unknown in humans. Rodent studies suggest a serum half-life of 10–30 minutes, but this may not translate directly. Once follistatin is cleared from the bloodstream, myostatin signaling resumes. This is why community protocols call for daily or twice-daily injection—to maintain suppression. No pharmacokinetic study has been done in humans.
Follistatin itself is not an androgen and does not directly suppress testosterone. However, it binds and inactivates activins, which regulate FSH secretion. Chronic activin suppression can lower FSH and, indirectly, may affect the hypothalamic-pituitary-testicular axis. Whether this translates to clinically meaningful testosterone suppression in humans is unknown—no one has measured it. Anecdotal reports from the performance community mention sexual dysfunction and testicular atrophy with follistatin use, but without hormone panels, causation cannot be confirmed. Fertility effects (sperm count, semen quality) are entirely unknown. This is a significant gap in our knowledge.
No. Follistatin peptides are not FDA-approved drugs; manufacturing and selling them for human use is illegal in the United States and most countries. Peptide suppliers market their products as “research chemicals—not for human consumption” to circumvent regulations, but the intention is clear. Athletes in drug-tested sports are banned from using it (WADA S4.4). Possession or use by non-athletes is technically illegal but rarely prosecuted. Law enforcement resources are directed toward large-scale trafficking, not individual users.
Terminology is inconsistent in the literature. The circulating form of follistatin is 315 amino acids long (after removal of a signal peptide). Some sources refer to this as “FS315”; others, using the pre-cleavage sequence, call it “FS344.” In practice, the peptides sold for performance enhancement are the ~35 kDa circulating form. Both terms refer to the same molecule. The distinction from FS288 (a shorter isoform) matters more biologically, but FS288 is less common in the performance community.
Related Peptides and Comparisons
Mechanical Growth Factor (MGF)
MGF is a splice variant of insulin-like growth factor-1 (IGF-1) produced in response to muscle damage and mechanical tension. It binds IGF-1 receptors and promotes muscle protein synthesis and satellite cell proliferation. Unlike follistatin, MGF does not inhibit myostatin directly. Instead, it drives anabolism through the IGF-1 pathway. MGF peptide has similarly minimal human trial data but is sometimes stacked with follistatin by underground experimenters. The mechanisms are complementary: follistatin removes the brake (myostatin), while MGF presses the gas (IGF-1 signaling).
| Compound | Type | Primary Target | Half-Life | FDA Status | WADA Status | Evidence Tier | Anabolic Mechanism | Myostatin Relationship | Route | Key Differentiator |
|---|---|---|---|---|---|---|---|---|---|---|
| Follistatin (Recombinant) | Recombinant human 315-amino-acid glycoprotein growth factor modulator | Activin / Myostatin antagonism (direct ligand sequestration); FSH modulation | ~4–6 hours (injection) | Not FDA-approved (investigational) | Prohibited — S2 (Growth factor, myostatin antagonist class) | Tier 3 — Pilot / Limited Human Data | Direct myostatin inhibition; muscle fiber hypertrophy (type II fast-twitch preferentially); systemic growth promotion | Direct myostatin sequestration/antagonism (primary mechanism); also inhibits activins broadly | Subcutaneous or intramuscular injection (research formulations; IV in clinical trials) | Broadest activin/myostatin antagonist in development. Phase IIb human data in muscular dystrophy (2020s). Natural myostatin brake |
| IGF-1 LR3 (Long-Arg3 IGF-1, Recombinant) | Recombinant human IGF-1 with N-terminal extended Arg residue (modified 71-amino-acid peptide, prolonged half-life variant) | IGF-1R (insulin-like growth factor 1 receptor); myostatin indirect inhibition via mTOR/PI3K pathway | ~20–30 hours (injection, extended half-life variant) | Not FDA-approved (investigational / research compound) | Prohibited — S2 (Growth factor, IGF-1 analog) | Tier 3 — Pilot / Limited Human Data | Systemic myotrophy (muscle protein synthesis enhancement via IGF-1R/mTOR); myonuclei proliferation; satellite cell activation | Indirect: mTOR activation suppresses myostatin signaling; does not directly bind myostatin | Subcutaneous or intramuscular injection | Extended half-life IGF-1 variant (~20–30 hr vs. 4–8 hr native IGF-1). Phase II human data limited; mostly anabolic steroid-adjacent history |
| IGF-1 DES (Desulfation, N-terminus deletion analog) | Recombinant human IGF-1 N-terminal-truncated variant (lacking first 3 amino acids: Gly-Pro-Glu) | IGF-1R (with ~3–4 fold increased local potency vs. native IGF-1); myostatin indirect antagonism | ~4–8 hours (injection) | Not FDA-approved (investigational / research compound) | Prohibited — S2 (Growth factor, IGF-1 analog) | Tier 3 — Pilot / Limited Human Data | Enhanced local IGF-1R activation (receptor selectivity favors myocytes); rapid muscle protein synthesis; myonuclei accretion | Indirect: mTOR pathway; no direct myostatin binding. Enhanced IGF-1R affinity may more potently suppress myostatin indirectly | Subcutaneous or intramuscular injection (local delivery optimized for muscle tissue) | Truncated variant with 3–4 fold higher potency at IGF-1R. Short half-life requires frequent dosing. Limited human data |
| MGF / PEG-MGF (Mechano-Growth Factor / Pegylated MGF, Recombinant) | Recombinant human IGF-1 Ec splice variant (49-amino-acid fragment with pegylation extension for PEG-MGF; extended half-life pegylated form) | IGF-1 Ec receptor signaling (local muscle growth factor); mechanical stress responsive; myostatin indirect antagonism | ~6–8 hours native MGF; ~24–36 hours pegylated (PEG-MGF) | Not FDA-approved (investigational / research compound) | Prohibited — S2 (Growth factor, IGF-1 analog/variant) | Tier 3 — Pilot / Limited Human Data | Mechanical stress-responsive growth factor; muscle damage repair and hypertrophy; myoblast proliferation and fusion (mechano-responsive) | Indirect: IGF-1 Ec splice variant activation of IGF-1R leading to mTOR suppression of myostatin; does not directly antagonize myostatin | Subcutaneous or intramuscular injection | Splice variant of IGF-1 responsive to mechanical loading. PEG-modified version extends half-life. Limited human clinical data |
IGF-1 LR3 (Long-Acting IGF-1)
IGF-1 Long-Arg3 is a modified version of IGF-1 engineered to have a longer half-life and resistance to IGF-binding proteins. Like MGF, it works via the IGF-1 receptor, not myostatin. It is used off-label in the performance community, again with no human safety or efficacy data. The combination of follistatin + IGF-1 LR3 theoretically provides both myostatin inhibition and growth factor signaling, though synergy is speculative.
Monoclonal Antibodies Against Myostatin (Domagrozumab, MYO-029)
These are large-molecule therapeutics (monoclonal antibodies) that bind and neutralize myostatin. They are in clinical development for Duchenne MD and other muscle diseases. Compared to follistatin peptide, they are larger (~150 kDa) and have longer half-lives (days to weeks), making them suitable for less frequent dosing (e.g., IV infusion every 4 weeks). None are currently approved by the FDA. These represent a potentially more refined approach than follistatin peptide—more specific targeting, better pharmacokinetics—but they are not available outside of clinical trials.
ActR2B Ligand Traps (ACE-031, Bimagrumab)
These engineered proteins act as “ligand traps,” binding and sequestering multiple TGF-β ligands (myostatin, activins, GDF11, others) by presenting a soluble version of the ActR2B receptor. They are in Phase II/III trials for muscle diseases. Like myostatin-specific antibodies, they offer more refined pharmacokinetics and specificity than systemic follistatin peptide, but they are not clinically available.
Comparison Table
| Agent | Mechanism | Half-Life (Estimated) | Human Data | Route | Community Use |
|---|---|---|---|---|---|
| Follistatin 344 | Myostatin + activin inhibition (high affinity) | ~10–30 min (estimated) | Gene therapy Phase I/II only; no peptide injection trials | SC injection | Yes; 100–200 mcg/day, 10–30 day cycles |
| MGF | IGF-1 signaling (promotes growth) | ~minutes (very short) | None | SC injection | Yes; often stacked with follistatin |
| IGF-1 LR3 | IGF-1 signaling (extended) | ~20–30 hours | None | SC injection | Yes; used for years in underground community |
| Domagrozumab (MYO-029) | Myostatin-specific monoclonal antibody | ~10–14 days (IV antibody) | Phase II trials in DMD (limited data) | IV infusion | Not available outside trials |
| Bimagrumab (ACE-031) | ActR2B ligand trap (multiple ligands) | ~7–14 days | Phase II/III (limited published data) | IV infusion or SC injection | Not available outside trials |
Summary
Follistatin is a validated myostatin inhibitor with rock-solid preclinical biology. Myostatin is a genuine negative regulator of muscle mass; removing it (or suppressing it) leads to muscle hypertrophy. This principle is proven in animals and has been clinically validated by AAV1-follistatin gene therapy trials in patients with muscle disease, where sustained intramuscular expression improved muscle function and walking distance.
But the peptide form—follistatin 344 injected subcutaneously for performance enhancement—exists in a regulatory and evidence vacuum. There are zero published human trials of follistatin peptide injection for muscle gain. The gene therapy data validates the mechanism, not the peptide application. The peptide is rapidly cleared, requires frequent dosing to maintain myostatin suppression, and has unknown effects on reproductive hormones (via activin suppression). Its safety and efficacy in humans for muscle enhancement are unvalidated.
The risks are not hypothetical. Chronic activin suppression is likely to lower FSH, affecting fertility and sexual function. Whether this is reversible upon cessation is unknown. Cardiac effects of sustained myostatin suppression are possible but not characterized in humans. Long-term consequences of systemic myostatin inhibition are unknown.
For athletes and self-experimenters, the choice is transparent. Use is banned in tested sports (WADA S4.4). Manufacturing and selling for human use is illegal. The online peptides are unregulated, of unknown purity and identity. The efficacy is speculative; the risks are real but incompletely understood. That is the honest evidence base.
For researchers and clinicians, myostatin inhibition remains a rich target for therapeutic development. Gene therapy approaches (AAV1-follistatin) are advancing. Monoclonal antibodies and receptor traps offer potentially superior pharmacokinetics. A properly designed Phase II trial of follistatin peptide in healthy humans could generate definitive efficacy and safety data—but such a trial has not been conducted, likely because the commercial incentive does not exist (peptides are not patentable at the scale of pharmaceutical development) and the ethical questions are difficult (randomizing people to receive an unproven, untested compound for performance enhancement is not defensible).
The research moves fast. We read all of it so you don’t have to.
New compound reviews, evidence updates, and protocol analysis — sourced, cited, and written for people who actually read the studies.
References
Further Reading
- Mendell, J. R., et al. “AAV Gene Therapy for Spinal Muscular Atrophy: An Emerging Treatment Option.” Neurology Today, 2023. (Reviews current status of AAV therapeutics in muscle disease.)
- Se-Jin Lee. “Quadrupedal Locomotion and Muscle Architecture: What We Can Learn from the Whippet.” Journal of Experimental Biology, 2015. (Reviews myostatin biology across species.)
- Manukhov, A. V., & Nasonov, E. L. (2019). “The Role of Follistatin in Immune Regulation and Inflammation.” International Journal of Molecular Sciences, 20(8), 1930. (Explores off-target effects of follistatin on immunity.)
- WADA Anti-Doping Rules and Prohibited Substances. https://www.wada-ama.org/ (Current regulations and testing protocols.)
- NIH Clinical Trials Database: Search “follistatin gene therapy” for ongoing and completed trials. https://clinicaltrials.gov/
← Previous
Next →